Triglycerides and cardiovascular risk

Heart

Volumn 99, Issue 1, 2013, Pages 1-2

  Jones, Alan ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EDITORIAL; FLUSHING; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SECONDARY PREVENTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; GUIDELINE ADHERENCE; HUMANS; HYPOLIPIDEMIC AGENTS; INCIDENCE; RISK FACTORS; TRIGLYCERIDES; WORLD HEALTH;

EID: 84871297951     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302968     Document Type: Editorial

References (18)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
2. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818.
3. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405-10. (Pubitemid 41446173)
4. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-28. (Pubitemid 44331360)
5. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1994;14:1767-74.
6. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007;357:1009-17.
7. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15. (Pubitemid 19043669)
8. Kasai T, Miyauchi K, Yanagisawa N, et al. Mortality risk of triglyceride levels in patients with coronary artery disease. Heart 2013;99:22-29.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
10. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
11. Wolfram RM, Brewer HB, Xue Z, et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 2006;98:711-17. (Pubitemid 44300998)
12. Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26:890-96. (Pubitemid 40676569)
13. Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009;104:459-63.
14. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after ccute coronary syndrome in the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol 2008;51:724-30. (Pubitemid 351221217)
15. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61.
16. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events VA-HIT: a Randomized Controlled Trial. JAMA 2001;285:1585-91. (Pubitemid 32240250)
17. The AIM-HIGH investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
18. http://www.controlled-trials.com/ISRCTN29503772 (accessed 21 Sep 2012).